Vaccine

Primary Series-Kittens

(< 16 weeks)

Primary Series-Adolescent/

Adult

(> 16 weeks)

Booster

Comments

Panleukopenia Virus (FPV) /Feline Herpesvirus-1 and Feline Calicivirus (FHV-1/FCV)

Injectable:

• MLV, non-adjuvanted

• Killed, adjuvanted (I)

• Killed, non-adjuvanted

Intranasal

• MLV, non-adjuvanted

Begin as early as 6 weeks of age, then every 3-4 weeks until 16 weeks of age.

2 doses, 3 to 4 weeks apart

A single dose is given 1 year following the last dose of the initial series, then no more frequently than every 3 years.

Core

• Killed vaccines are preferred for use in pregnant cats (and only if absolutely necessary) and in FeLV and/or FIV infected cats, especially those showing evidence of immunosuppression.
• Killed panleukopenia vaccines should be used in kittens less than 4 weeks of age.  

• All kittens and cats should receive at least one injectable panleukopenia injection.

.

Rabies^e

Injectable:

• Canarypox virus-vectored recombinant (rRabies), non-adjuvanted
• 1-year killed, adjuvanted^a
• 3-Year killed, adjuvanted^a

Administer a single dose as early as 8 or 12 weeks of age depending on the product label. Revaccinate 1 year later.

Administer 2 doses, 12 months apart.

Annual booster is required.

Vs. Every 3 years or as required by State or local ordinance for 3-year

Core

• In States and municipalities where feline rabies vaccination is required, veterinarians must follow applicable statutes.
• Booster vaccination with a 1-year rabies vaccine is only appropriate in States and municipalities where permitted by law.
• Any rabies vaccine can be used for revaccination, even if the product is not the same brand or type of product previously administered.  (III)
• No laboratory or epidemiologic data exist to support the annual or biennial administration of 3-year vaccines following the initial series.

Feline Leukemia Virus (FeLV)

Transdermal:

• Canarypox virus-vectored recombinant (rFeLV), non-adjuvanted

Injectable

• Or Killed, adjuvanted

Administer an initial dose as early as 8 – 12 weeks of age, depending on product; a second dose should be administered 3-4 weeks later.

2 doses, 3 to 4 weeks apart

When indicated, a single dose is given 1 year following the last dose of the initial series, then annually in cats determined to have sustained risk of exposure. ^f

Non-Core

• Killed, adjuvanted^a

When indicated, 3 doses are required:

The initial dose is administered as early as 8 weeks of age; 2 subsequent doses should be administered at an interval of 2-3 weeks. 

When indicated, 3 doses are required:

Each dose is administered 2-3 weeks apart.

When indicated, a single dose is given 1 year following the last dose of the initial series, then annually in cats determined to have sustained risk of exposure.^h

Non-Core

• FIV vaccine should be restricted to cats at high risk of infection. (IV)
• Vaccination induces production of antibodies indistinguishable from those developed in response to FIV infection, and interferes with all antibody-based FIV diagnostic tests for at least a year following vaccination.
• Cats with positive FIV antibody assay results may have antibodies as a result of vaccination, infection, or both.
• FIV antibodies are passed from vaccinated queens to their kittens in colostrum. Colostrum-derived antibodies interfere with FIV diagnosis past the age of weaning in the majority of kittens, but this interference appears to wane by 12 weeks of age.
• Cats should test FIV-antibody negative immediately prior to vaccination.
• Permanent identification of vaccinated cats (e.g., using a microchip) will help clarify vaccination status, but will not indicate that such cats are free of infection.
• This vaccine has been shown to provide protection from some, but not all, strains of FIV.

Feline Infectious Peritonitis (FIP)

• MLV, non-adjuvanted

• Intranasal

If administered, give a single dose as early as 16 weeks of age, and a second dose 3-4 weeks later. 

If administered, give 2 doses, 3-4 weeks apart.

Annual booster is recommended by the manufacturer.

Not Generally Recommended

• According to the limited studies available, only cats known to be feline coronavirus antibody negative at the time of vaccination are likely to develop some level of protection.
• Vaccination of cats living within households in which FIP is known to exist or cats that are known to be feline coronavirus antibody positive is not recommended. 

Chlamydophila felis

• Avirulent live, non-adjuvanted
• Or killed, adjuvanted

• Injectable

Administer the initial dose as early as 9 weeks of age; a second dose is administered 3-4 weeks later.

Administer 2 doses, 3-4 weeks apart.

Annual booster is indicated for cats with sustained exposure risk.

Non-Core

• Vaccination reserved as part of a control regime for cats in multiple-cats environments where infections associated with clinical disease have been confirmed. 
• Inadvertent conjunctival inoculation of vaccine has been reported to cause clinical signs of infection.

Bordetella bronchiseptica

• Avirulent live, non-adjuvanted

• Intranasal

Administer a single dose intranasally as early as 8 weeks of age. 

Administer a single dose intranasally

Annual booster is indicated for cats with sustained risk.

Non-Core

• Vaccination may be considered in cases where cats are likely to be at specific risk of infection. (V) 

Feline Giardia

• Killed, adjuvanted^a

• Injectable

Administer a single dose at 8 weeks of age; a second dose is administered 2-4 weeks later.

2 doses, 2-4 weeks apart.

Annual booster is recommended by the manufacturer.

Not Generally Recommended

• There are insufficient studies available to support the role of Giardia vaccination in preventing clinical disease in cats.
• Whether the Giardia vaccine is an effective therapeutic agent in naturally infected cats is currently unknown.